ACE-031

Description

Pharmacokinetics 

ACE-031’s mechanism of action rests within blocking chemical signals that inhibit muscle growth. Circulating outside of muscle-fiber membranes, ACE-031 binds to a type of myokine called myostatin. Typically, myostatin limits muscle growth by halting the chemical signals of cells, stopping myogenesis. However, it appears that ACE-031 binds to myostatin, therefore limiting restraining signals and allowing for increased muscle growth.[3]

Scientific Studies

There have been multiple clinical studies on ACE-031, many focused on treating children with Duchenne muscular dystrophy, or DMD. In a study focusing on boys with DMD, ACE-031 was administered once every 2 to 4 weeks. By the end of the study, trends indicating muscle retention and fat loss were noted.[4] Another trial conducted on postmenopausal women also seemed to indicate increased muscle mass.[2]

Sources:

[1] http://investor.acceleronpharma.com/news-releases/news-release-details/acceleron-pharmas-ace-031-increases-muscle-mass-preclinical

[2 ]https://www.ncbi.nlm.nih.gov/pubmed/23169607

[3] https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.23539

[4] https://www.ncbi.nlm.nih.gov/pubmed/27462804

[5] https://www.mda.org/quest/article/update-ace-031-clinical-trials-duchenne-md

Additional information